Biocon launches Yesafili, a U.S. biosimilar to Eylea® 2 mg

Biocon launches Yesafili, a U.S. biosimilar to Eylea® 2 mg — Biocon has announced the U.S. commercial launch of Yesafili, a biosimilar to Regeneron’s Eylea® 2 mg. The launch marks a major expansion into the U.S. ophthalmology market, targeting $4 billion in annual sales. This move strengthens Biocon’s global footprint and potential revenue streams.
📊 STOCKS: $BIOCON | 🏢 SECTOR: Pharma | #HIGHIMPACT #Biosimilar